Federal multidistrict litigation tracker

MDL 3094 Update — Ozempic / GLP-1 Lawsuit

In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation. Counts are monthly JPML snapshots and can change between reports.

Lawsuit status — September 2026

Ozempic / GLP-1 Lawsuit

Verified September 15, 2026

MDL: MDL-3094
Court: E.D. Pa.
Judge: Judge Karen Spencer Marston
Pending cases: 4,022; +94 since prior report
Current phase: Rule 702 evidentiary hearing in progress September 14–18, 2026
Settlement status: No public settlement program identified
Latest development: JPML reports 4,022 pending actions on September 1, 2026, compared with 3,928 on August 3; 4,056 total historical actions are reported separately.
Next major event: September 18, 2026 — Rule 702 evidentiary hearing runs through September 18

What changed this month?

●JPML reports 4,022 pending actions on September 1, 2026, compared with 3,928 on August 3; 4,056 total historical actions are reported separately. Source
●An August 28 order rescheduled the Rule 702 evidentiary hearing to September 14–18, 2026. It is not a jury trial. Source
●The separate NAION vision-loss MDL-3163 has 216 pending actions as of September 1, compared with 200 on August 3. Source
●The public MDL orders checked September 14 contain no announced bellwether trial date or settlement program. Source

MDL details

Created: February 2, 2024
Pending: 4,022
Total actions filed: 4,056
Monthly change: +94

Defendants named in the tracked record

Novo Nordisk (Ozempic, Wegovy, Rybelsus, Saxenda); Eli Lilly (Mounjaro, Zepbound, Trulicity). Defendants dispute the allegations.

Historical case counts

Report	Pending	Total filed
September 1, 2026	4,022	4,056
August 3, 2026	3,928	3,962

What the litigation alleges

The tracked claims concern prescription drug injury claim (federal mdl), including gastroparesis and severe gastrointestinal injuries. These are allegations; defendants dispute liability and causation.

Stage and bellwether status

The Eastern District of Pennsylvania's remote-access page states that Judge Marston is holding the Rule 702 evidentiary hearing from September 14 through September 18, 2026. This is an expert-evidence hearing, not a bellwether trial, and the court has not announced an outcome. NAION vision-loss claims are coordinated separately in MDL-3163.

Settlement status

The Eastern District of Pennsylvania public MDL orders reviewed September 14, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The scheduled Rule 702 hearing concerns expert evidence, not settlement eligibility or an individual award.

Individual claims: The Eastern District of Pennsylvania public MDL orders reviewed September 14, 2026 do not announce a GLP-1 injury settlement program or official payout amounts. The scheduled Rule 702 hearing concerns expert evidence, not settlement eligibility or an individual award.